ArticleTherapeutic advances in medical oncology2025

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study.

Glenwood Goss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.